Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High – Should You Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) hit a new 52-week high during trading on Tuesday . The company traded as high as $82.26 and last traded at $81.40, with a volume of 100975 shares trading hands. The stock had previously closed at $80.78.

Analysts Set New Price Targets

Several research analysts recently commented on HALO shares. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Finally, Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Down 1.5%

The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 28.91, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84. The firm has a 50 day simple moving average of $70.33 and a 200-day simple moving average of $69.79. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 72,179 shares of company stock valued at $5,052,400. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Gradient Investments LLC acquired a new position in Halozyme Therapeutics in the second quarter valued at approximately $1,287,000. Assenagon Asset Management S.A. raised its position in shares of Halozyme Therapeutics by 4,578.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock valued at $78,086,000 after acquiring an additional 976,321 shares during the last quarter. Balefire LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $230,000. GAMMA Investing LLC lifted its stake in shares of Halozyme Therapeutics by 13.7% in the 2nd quarter. GAMMA Investing LLC now owns 4,487 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 542 shares during the period. Finally, Harbor Investment Advisory LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $117,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.